Ross Aldred, 43, discovered he had advanced bowel cancer that had spread to his liver, spleen, lungs, and lymph nodes, a diagnosis that has brought to light a growing medical concern: the increasing incidence of bowel cancer in adults under 50. Aldred, who is vegan, does not drink, and exercises regularly, shared his story from a hospital bed, detailing the unexpected chain of events leading to his diagnosis. His experience, documented on Instagram, has resonated with many, partly due to the 'terrifying reality' that bowel cancer is increasingly affecting younger demographics.
Diagnoses of bowel cancer among adults under 50 have risen by approximately 50 percent since the 1990s. This trend is occurring even in individuals who are otherwise healthy. Medical professionals report treating a significant number of young, healthy patients, many of whom are diagnosed at late stages. Dr. Ravindhi Murphy, a consultant medical oncologist, notes that these cases are either missed due to assumptions about age or are particularly aggressive forms of the disease.
Aldred's symptoms began subtly with small lumps on his neck, which he initially dismissed as a sign of being run down. Despite urgent referrals and initial reassurances from a specialist that the lumps were likely benign, his condition rapidly worsened. Within days, he experienced severe abdominal pain and began vomiting, eventually leading to emergency room visits where scans revealed growths on his liver. Further investigations, including an endoscopy and colonoscopy, confirmed the devastating diagnosis.
The cancer had progressed to stage four, significantly reducing his prognosis. Aldred underwent an emergency operation to address an 11mm tumor blocking his bowel and subsequently faced complications with his liver function, which posed a risk for chemotherapy treatment. He underwent a high-risk procedure to drain toxins from his liver, followed by sepsis, from which he remarkably recovered.
Genetic testing revealed Aldred's cancer to be a BRAF subtype, an aggressive form of the disease that can respond well to specific targeted therapies. This subtype is also associated with younger patients. While a combination of drugs like encorafenib and cetuximab alongside chemotherapy has shown to significantly improve life expectancy in international studies, this treatment is not routinely available on the NHS in the UK. Private treatment is prohibitively expensive, prompting Aldred and his husband to launch a fundraising appeal. He is set to begin the targeted treatment, expressing a positive outlook and a renewed appreciation for life and loved ones.